CD274 and non-small cell lung carcinoma: PD‐1/PD‐L1 inhibitors in several three‐phase clinical trials prolonged survival times and decreased adverse events during NSCLC treatment, especially when patients had a high PD‐L1 expression (≥50%).9, 10, 11, 12, 13